VYNE Therapeutics
Menlo Park
About VYNE Therapeutics
VYNE Therapeutics is a clinical late-stage biopharmaceutical company that focuses on the development and commercialization of serlopitant for the treatment of pruritus (itch) associated with dermatologic conditions such as atopic dermatitis, psoriasis, and prurigo nodularis.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $297.8M
- Funding stage: M&A
- Last round: Post-IPO Equity (Oct 2023)
- Ticker: nasdaq:VYNE
- Website: vynetherapeutics.com
- Phone: (650)486-1416
Industries & Categories
Health Care, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/vyne-therapeutics-121799 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.